



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2006-005969-18/ Novartis Protocol ID CLAF237A23122

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared to Metformin 1000 mg bid in Drug-naïve Patients with Type 2 Diabetes

Trial CLAF237A23122 was cancelled with no patient enrollment and as such, no results will be reported.